Search

for
Search:

Community Join

5 / 736 results

community New warning by FDA on topical finasteride

in Research/Science 194 upvotes 1 year ago

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

community A warning to anyone considering 3rd party sourcing PP405 or its analogs

30 upvotes 5 months ago

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

community Warning: finasteride to dutasteride switch

in Finasteride/Dutasteride 73 upvotes 1 year ago

Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.

community A warning to those using or thinking about using Dutasteride – Follow-up

18 upvotes 5 years ago

The post and conversation are about the long-term side effects of using Dutasteride and Finasteride for hair loss, including issues like raised liver enzymes, high cholesterol, and loss of libido. The user advises regular blood work and careful monitoring for those using these treatments.

community A warning to those thinking about using Dutasteride

in Finasteride/Dutasteride 99 upvotes 6 years ago

The potential risks of long-term use of Dutasteride and how it may be linked to elevated liver enzymes, cholesterol levels, and decreased testosterone. Alternative treatments such as Finasteride and RU58841 were also discussed.

View more "fda warnings" in community →

Research

5 / 1000+ results

research Synthetic hair implantations continue; serious complications result

8 citations , June 1979 in “JAMA”

This article discussed the ineffectiveness and dangers of implanting synthetic hair fibers for pattern baldness, noting they can cause severe infections, yet such clinics remain operational.

research Synthetic hair implantations continue; serious complications result

2 citations , June 1979 in “JAMA”

This article reviews the ineffectiveness and potential dangers of synthetic fiber implantation for pattern baldness and reports no resolution of their ongoing use despite safety concerns.

research Global online interest in finasteride sexual side effects

September 2022 in “International Journal of Impotence Research”

This study found that global online interest in finasteride and its sexual side effects significantly increased after the FDA issued safety warnings in 2011.

research Assessment of biotin supplementation among patients in an outpatient dermatology clinic

13 citations , January 2019 in “Journal of the American Academy of Dermatology”

This study found that biotin supplementation is common among patients at a dermatology clinic despite a lack of evidence for its dermatologic benefits and potential interference with lab tests.

research Biotin beware: Perils of biotin supplementation: Response to: “The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins”

1 citations , February 2022 in “Journal of the American Academy of Dermatology”

This review discusses biotin supplementation for dermatological conditions and highlights the lack of strong evidence supporting its efficacy, as well as the potential for laboratory testing interference.

View more "fda warnings" in research →

Learn

1 / 801 results

learn Tofacitinib

How does tofacitinib differ when used orally versus topically in hair loss treatment research? Oral tofacitinib acts on immune signalling throughout the body and has the stronger regrowth evidence in alopecia areata, alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.

View more "fda warnings" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →